Niagen Bioscience Leads The Way With 2 Promising Penny Stocks
This article highlights two penny stocks, Niagen Bioscience (NAGE) and Nutriband (NTRB), that show promise despite the inherent volatility of smaller companies. Niagen Bioscience, with a market cap of US$251.36 million, is expanding its healthy aging products and maintains a debt-free balance sheet. Nutriband, valued at US$43.15 million, is developing transdermal pharmaceutical products and has strengthened its financial position with a new credit line.
Supplement Retail Expansions
Niagen Bioscience has expanded the retail availability of its Tru Niagen product line, including Tru Niagen Beauty, into GNC and Sam's Club stores across 44 states. This move signifies a broader trend of science-backed healthy aging supplements transitioning from niche wellness shops to mainstream retail, making advanced cellular health products more accessible to everyday consumers. The expansion highlights growing consumer interest in NAD+ support for cellular energy, mitochondrial function, and DNA repair, as well as the increasing market for beauty-from-within ingestible supplements.
Niagen Bioscience expands Tru Niagen to GNC, Sam’s Club stores
Niagen Bioscience (NASDAQ:NAGE) announced that its Tru Niagen supplement is now available at GNC and Sam’s Club retail locations and online, significantly expanding its retail footprint to nearly 300 stores across 44 states. The expansion includes different product sizes and formulations for each retailer. Tru Niagen is an NAD+ boosting supplement backed by extensive clinical studies.
Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam’s Club
Niagen Bioscience has expanded the retail availability of its Tru Niagen® supplement, now offering it at GNC and Sam's Club stores and online. This move strengthens the company's retail presence and makes the NAD-boosting healthy-aging supplement accessible to a broader consumer base across 44 states. Tru Niagen® is supported by extensive clinical studies and patents, affirming its scientific backing and quality standards.
Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam’s Club
Niagen Bioscience announced that its Tru Niagen® healthy aging supplement is now available at nearly 300 GNC and Sam’s Club locations across 44 states and online. This expansion includes Tru Niagen Beauty at GNC and various Tru Niagen 300mg bottle counts at both retailers, significantly strengthening its retail presence. The move reflects growing consumer demand for science-backed healthy aging solutions, leveraging Tru Niagen's clinically proven NAD+ boosting capabilities.
Tieton Capital Management LLC Purchases New Position in Niagen Bioscience, Inc. $NAGE
Tieton Capital Management LLC has acquired a new position in Niagen Bioscience, Inc. (NASDAQ:NAGE), purchasing over 2 million shares valued at approximately $6.4 million, representing 1.8% of their investment portfolio. Other institutional investors have also recently bought into Niagen Bioscience, with hedge funds and institutional investors collectively owning 15.41% of the company's stock. Analysts generally maintain a "Buy" rating for NAGE, with a consensus price target of $10.33, despite the stock trading significantly below its 52-week high.
Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
Niagen Bioscience has partnered with Evotec to advance the preclinical development of NB4168, their lead investigational candidate for rare pediatric diseases, particularly Ataxia Telangiectasia (A-T). Evotec will conduct pharmacokinetic, pharmacodynamic, and bioanalytical studies at their Verona campus, utilizing their INDiGO platform to accelerate the development process. NB4168 is a proprietary oral small-molecule designed to increase NR exposure, supporting NAD+ pathways that are disrupted in A-T, and has received Rare Pediatric Disease and Orphan Medicinal Product Designations.
Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence
Niagen Bioscience has launched its leading healthy-aging NAD+ supplement, Tru Niagen, on Walmart.com, significantly expanding its e-commerce reach and consumer access. This move allows more consumers nationwide to purchase the clinically proven supplement, which is backed by extensive scientific research and helps support cellular function and healthy aging. The initial rollout includes 300 mg bottles, with more products to follow, capitalizing on Walmart's growing digital platform and health and wellness sales.
Niagen Bioscience launches Tru Niagen on Walmart.com
Niagen Bioscience has launched its Tru Niagen NAD+ supplement on Walmart.com, making its healthy-aging product more widely available. The initial offering includes 300 mg bottles, with more products to follow. Tru Niagen, which contains patented nicotinamide riboside, is backed by numerous human clinical studies and is cited as the top-selling NAD+ supplement in the U.S. e-commerce market.
Sei Investments Co. Increases Holdings in Niagen Bioscience, Inc. $NAGE
Sei Investments Co. significantly increased its stake in Niagen Bioscience, Inc. (NASDAQ:NAGE) by 155.6% in the first quarter, now owning 971,574 shares valued at $4.29 million. Despite this increased institutional interest, Niagen Bioscience shares opened down 14.7% near their 52-week low, with quarterly earnings matching expectations but revenue falling slightly short. Analysts maintain a generally positive outlook with an average "Buy" rating and a consensus price target of $10.33.
Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence
Niagen Bioscience has launched its Tru Niagen supplement on Walmart.com, significantly broadening consumer access to its leading healthy-aging NAD+ product. This move diversifies Niagen Bioscience's e-commerce presence, leveraging Walmart's substantial digital reach and health and wellness market share. The initial offering includes 300 mg Tru Niagen in 30-count and 90-count bottles, with more products to follow, aiming to meet consumers where they shop.
Q2 2026 Niagen Bioscience Inc Earnings Call Transcript
This document provides the earnings call transcript for Niagen Bioscience Inc.'s (NAGE) second quarter of 2026. Key points highlight strong e-commerce growth, expansion into new verticals like skincare and IV/injection, a robust balance sheet, and progress in its pharmaceutical pipeline. However, the report also notes negative aspects such as lower ingredient business revenue, increased selling and marketing expenses, and a decline in net income.
Niagen Bioscience, Inc. Stock 12‑Month Price Target Cut to $12.08, Implies 248% Upside
Niagen Bioscience, Inc.'s average stock price target has been reduced slightly from $12.42 to $12.08 by 6 analysts, with forecasts ranging from $8.5 to $22 per share. Despite the cut, the updated target suggests a 248% potential upside based on the August 4th closing price. The consensus rating for the stock remains a "Buy" from all 6 covering analysts.
Niagen Bioscience (NAGE) On New Aging Study And The Case For A Higher Fair Value
Niagen Bioscience (NAGE) is gaining attention after a new study linked its Niagen nicotinamide riboside supplementation to reduced muscle epigenetic age acceleration. Despite recent stock price declines, the company's valuation is seen as undervalued at $2.96 compared to a fair value of $12.60, driven by anticipated growth in pharmaceutical-grade Niagen and e-commerce. However, risks related to regulatory outcomes and potential pressure on margins remain.
CCORF Maintains Niagen Bioscience(NAGE.US) With Buy Rating, Maintains Target Price $10
CCORF has reiterated its Buy rating for Niagen Bioscience (NAGE.US) and maintained its target price at $10. This indicates a continued positive outlook from the firm regarding Niagen Bioscience's stock performance.
Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
Niagen Bioscience, Inc. announced its Q2 2026 financial results, reporting net sales of $29.8 million and a net income of $1.0 million. The company also highlighted strategic advancements, including the launch of its Niagen Plus telehealth platform and the introduction of NB4168, a pharmaceutical candidate for rare genetic and aging-related diseases. Niagen Bioscience is transitioning into a multi-asset anti-aging company, leveraging its consumer business to fund new growth initiatives.
Niagen Bioscience Inc (NAGE) (Q2 2026) Earnings Call Highlights: E-Commerce Surge and China ...
Niagen Bioscience Inc (NAGE) reported robust Q2 2026 results, driven by significant e-commerce growth, particularly on its TrueNiagen website and Amazon, and impressive expansion in the China cross-border market. The company is strategically diversifying into new high-growth verticals like skincare and IV/injection therapies, backed by a strong balance sheet and advancements in its pharmaceutical pipeline. Despite facing challenges such as increased marketing expenses, declining net income, and competitive pressures in its ingredient business, NAGE remains focused on long-term growth and shareholder value, with ongoing legal battles, retail expansions, and pharma developments outlined during the earnings call.
Niagen Bioscience, Inc. (NASDAQ:NAGE) Given Consensus Rating of "Buy" by Brokerages
Niagen Bioscience, Inc. (NASDAQ:NAGE) has received a consensus "Buy" rating from five brokerages, with an average 12-month price target of $10.33. Despite the positive analyst sentiment, the company's shares recently traded down to $3.06, near its 52-week low. Institutional investors hold a significant 15.41% stake in the company, which reported quarterly EPS of $0.01, meeting estimates, and revenue slightly below forecasts.
Earnings call transcript: Niagen Bioscience posts q2 2026 growth, lifts spending
Niagen Bioscience (CDXC) reported Q2 2026 revenue of $29.8 million, driven by growth in its Tru Niagen supplement and e-commerce, but net income dropped to $1 million ($0.01 per diluted share) due to increased marketing and product development spending. The company is transitioning into a broader "NAD platform company" with ventures into consumer health, injectable/IV products, skincare, and pharmaceuticals. Management views 2026 as an investment year, anticipating future growth from these new initiatives while maintaining a strong balance sheet.
Niagen Bioscience (NASDAQ:NAGE) Announces Quarterly Earnings Results, Meets Expectations
Niagen Bioscience (NASDAQ:NAGE) reported quarterly earnings of $0.01 EPS, which met analyst expectations. The company demonstrated a net margin of 14.29% and a return on equity of 22.68%. Despite the stock trading near its 52-week low, analysts maintain a generally positive "Buy" rating with an average price target of $10.50.
Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
Niagen Bioscience, Inc. announced its Q2 2026 financial results, reporting net sales of $29.8 million and a net income of $1.0 million. The company highlighted the launch of its Niagen Plus telehealth platform and the pharmaceutical program targeting rare genetic diseases with its investigational therapeutic candidate, NB4168. Niagen Bioscience also provided a 2026 outlook, forecasting 10% to 15% growth for its e-commerce business and strategic investments in its pharmaceutical and telehealth initiatives.
Niagen Bioscience (NAGE) FDA Approvals, PDUFA Dates & Drug Alerts 2026
Niagen Bioscience (NAGE) is advancing its drug candidate NB4168 for the treatment of Ataxia Telangiectasia. The company recently announced that it has selected Evotec as a contract research organization to support NB4168's development and previously received Rare Pediatric Disease designation from the FDA for this drug. While NB4168 is undergoing regulatory review, Niagen Bioscience has not yet received any FDA approvals for its therapies in the last two years.
Niagen Bioscience selects Evotec for rare disease drug studies
Niagen Bioscience has partnered with Evotec to support the development of NB4168, an oral small-molecule candidate for Ataxia Telangiectasia (A-T), a rare pediatric genetic disease. Evotec will conduct pharmacokinetic and pharmacodynamic studies and validate bioanalytical methods for NB4168. Niagen Bioscience plans to submit an Investigational New Drug application to the FDA for human clinical studies of NB4168, which has already received Rare Pediatric Disease and Orphan Medicinal Product designations.
Evotec to Study NB4168 for Rare Pediatric Disease With No Approved Treatment
Niagen Bioscience has partnered with Evotec, a global life science company, to advance the preclinical development of NB4168, a proprietary oral small-molecule candidate for Ataxia Telangiectasia (A-T), a rare pediatric genetic disease with no approved treatments. Evotec will conduct pharmacokinetic, pharmacodynamic, and bioanalytical studies at its Verona campus, utilizing its INDiGO platform to streamline the path to clinical evaluation. This collaboration aims to generate the necessary pharmacological and bioanalytical evidence to progress NB4168 toward human clinical studies, supported by its existing Rare Pediatric Disease and Orphan Medicinal Product Designations.
Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
Niagen Bioscience has partnered with Evotec to advance the preclinical development of NB4168, their lead investigational candidate for rare pediatric diseases like Ataxia Telangiectasia (A-T). Evotec will conduct pharmacokinetic, pharmacodynamic, and bioanalytical studies at their Verona campus, leveraging their INDiGO platform to streamline development. This collaboration aims to generate crucial data to support Niagen Bioscience's Investigational New Drug (IND) application for NB4168, which has already received Rare Pediatric Disease Designation from the FDA and Orphan Medicinal Product Designation from the EMA.
Arrowstreet Capital Limited Partnership Buys 761,685 Shares of Niagen Bioscience, Inc. $NAGE
Arrowstreet Capital Limited Partnership significantly increased its stake in Niagen Bioscience, Inc. (NASDAQ:NAGE) by purchasing 761,685 additional shares in the first quarter, bringing its total holdings to 2,378,437 shares valued at $10.489 million. Other institutional investors like JPMorgan Chase & Co., SteelPeak Wealth LLC, and UBS Group AG also modified their positions. The article also provides Niagen Bioscience's recent price performance, earnings data, and analyst ratings, which show a consensus "Buy" rating with an average price target of $10.50.
Niagen Bioscience Inc (NAGE) Institutional Confidence
Niagen Bioscience Inc (NAGE) has an institutional shareholding score of 3.00, placing it 191st out of 384 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 38.95%, reflecting a 23.33% decrease quarter-over-quarter. James Simons is the largest institutional shareholder with 1.67% of shares outstanding.
Niagen Bioscience, Inc. Revenue Breakdown – DUS:OCD1
Niagen Bioscience, Inc. (OCD1) generated €110.19 million in revenue last year. The Consumer Products segment was the top performer, contributing €83.16 million, and the United States was the largest regional contributor, accounting for €86.50 million in revenue.
Niagen Bioscience reports study on muscle aging markers By Investing.com
Niagen Bioscience Inc. announced the publication of a peer-reviewed analysis in Aging Cell, which found that Niagen nicotinamide riboside supplementation for five months was associated with reducing muscle epigenetic age acceleration by approximately 2.5 years. The study involved analyzing skeletal muscle and blood samples from three previous clinical trials, with six out of seven epigenetic clocks showing changes consistent with lower epigenetic age acceleration. The company notes that these findings are preliminary, stemming from a secondary analysis of previously conducted studies.
NAGE|Niagen Bioscience Inc|Price:3.270|Chg%:+0.040
Niagen Bioscience Inc (NAGE) is rated "Buy" by multiple analysts with a target price of $12.50, indicating a significant upside potential of 289.41%. The company has strong fundamentals, including 3-year average revenue growth of 54.87%, and an undervaluation with a P/E of 13.83. Despite positive analyst sentiment and growth, the stock is expected to trend down in the medium term, currently trading sideways, and is considered fairly valued within its industry.
Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference
Niagen Bioscience, Inc. announced that its CEO, Rob Fried, and CFO, Ozan Pamir, will participate in Canaccord Genuity’s 46th Annual Growth Conference from August 11-13, 2026, in Boston. Mr. Fried is scheduled for a fireside chat on August 11, and both executives will hold one-on-one meetings with institutional investors. The company, specializing in NAD+ science for healthy aging, invites registration for the webcast of the fireside chat and provides links to its investor relations website for further information.
Niagen Bioscience Inc (NAGE) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides details on the dividend and stock split history for Niagen Bioscience Inc (NAGE). It states that the company has distributed $0.00 in dividends over the past five years and shows no historical data for dividend payment dates. The article includes current stock trading information and company financials.
Niagen Bioscience, Inc. Revenue Breakdown – TRADEGATE:OCD1
Niagen Bioscience, Inc. (OCD1) generated 110.19 million EUR in revenue last year, with its Consumer Products segment being the top performer, contributing 83.16 million EUR. The United States market was the largest regional contributor, accounting for 86.50 million EUR of the company's revenue. This financial snapshot highlights key revenue streams and geographic performance for the company.
Niagen Bioscience to report Q2 2026 results on August 4
Niagen Bioscience, Inc. is scheduled to announce its financial results for the second quarter ending June 30, 2026, on Tuesday, August 4, 2026, after market close. A conference call will follow at 4:30 p.m. ET to discuss the results and provide a business update for the company, which specializes in NAD+ science and healthy aging solutions. The earnings press release and financial exhibits will be available on the company's Investor Relations website.
Niagen Bioscience Appoints Dr. Abhijit Kale to Lead Global NAD+ Research
Niagen Bioscience has appointed Dr. Abhijit Kale as Senior Director of Global External Research to lead its Niagen Research Program. Dr. Kale, with over a decade of experience in aging biology and translational science, will oversee global academic and clinical research collaborations to advance understanding of NAD+ biology and healthy aging. This appointment aims to strengthen Niagen Bioscience's position as a leader in NAD+ research and expand its scientific initiatives.
Press Release: Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
Niagen Bioscience has announced that it will release its second quarter 2026 financial results on Tuesday, August 4, 2026. The company will also host a conference call and webcast on the same day to discuss the results. Management will be available for a question-and-answer session following the prepared remarks.
SteelPeak Wealth LLC Makes New Investment in Niagen Bioscience, Inc. $NAGE
SteelPeak Wealth LLC has made a new investment in Niagen Bioscience, Inc. (NASDAQ:NAGE) during the first quarter, acquiring 3,373,000 shares valued at approximately $14.88 million. This new stake represents about 4.24% of the company. Other institutional investors have also adjusted their positions in Niagen Bioscience, which recently reported earnings per share of $0.07, surpassing analyst expectations, and maintains an average "Buy" rating with a consensus price target of $10.50.
Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research
Niagen Bioscience, Inc. has appointed Abhijit Kale, Ph.D., as Senior Director of Global External Research, effective July 20, 2026. Dr. Kale will lead the Global Niagen Research Program, overseeing collaborations and shaping the scientific research strategy related to NAD+ biology and healthy aging. He brings over a decade of experience and will focus on expanding the program into emerging areas of NAD+ science.
Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research
Niagen Bioscience has appointed Dr. Abhijit Kale as Senior Director of Global External Research, effective July 20, 2026. Dr. Kale will lead the company's Global Niagen Research Program, overseeing collaborations and shaping scientific strategy related to NAD+ biology and healthy aging. This appointment is expected to deepen Niagen Bioscience's research efforts and expand its leadership in NAD+ science.
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)
Niagen Bioscience has received both U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168, a novel small molecule therapy for Ataxia Telangiectasia (A-T). These designations highlight the significant unmet medical need for A-T, a rare genetic premature aging disease with no approved treatments, and will help accelerate the development of NB4168, which aims to increase NAD+ levels to address DNA repair, mitochondrial function, and cellular energy disruptions. The company plans to advance preclinical development and submit an IND application to the FDA for clinical studies.
Niagen Bioscience receives FDA, EMA designations for rare disease drug
Niagen Bioscience has received Rare Pediatric Disease Designation from the FDA and Orphan Medicinal Product Designation from the EMA for its drug candidate NB4168, which treats Ataxia Telangiectasia. This rare genetic disease currently has no FDA-approved therapies. Despite a 70% stock decline over the past year, InvestingPro suggests the stock is undervalued, and analysts have reiterated Buy ratings, highlighting the company's ongoing drug development and intellectual property protection efforts.
Niagen Bioscience files prospectus to offer common stock up to $50M
Niagen Bioscience has filed a prospectus with the SEC to offer and sell up to $50 million in common stock. This move is part of the company's financial strategy to raise capital for future growth, operations, and expansion initiatives. The prospectus details the offering type and maximum amount, aiming to attract investors and fund its business objectives.
Form 424B5 Niagen Bioscience Inc For: 10 July By Investing.com
This article reports on the filing of Form 424B5 by Niagen Bioscience Inc. on July 10, 2026. It mentions the company's stock symbol NAGE, which saw a -2.87% change. The content primarily consists of a single sentence announcing the filing, surrounded by numerous navigational links and market data.
Form 424B5 Niagen Bioscience Inc For: 10 July By Investing.com
This article announces the filing of Form 424B5 by Niagen Bioscience Inc. on July 10. The content itself seems to be a placeholder or a very brief report, as it repeats the headline multiple times and is surrounded by what appears to be website navigation and market data, rather than detailed article text. The stock symbol NAGE is mentioned with a -2.87% change.
Niagen Bioscience, Inc. SEC Filing (Jul 10, 2026)
This article reports on an SEC filing by Niagen Bioscience, Inc. (NAGE) on July 10, 2026, which was a Notice of Effectiveness for an S-3 form. The filing indicates the company's S-3 form became effective on July 9, 2026, at 4:05 P.M. The article also provides recent news and SEC filings related to Niagen Bioscience, including their upcoming financial results report and recent FDA designations.
Niagen Bioscience (NAGE) CFO acquires stock through employee purchase plan
Niagen Bioscience's CFO, Pamir Ozan, acquired 4,255 shares of common stock at $2.71 per share through the company's Employee Stock Purchase Plan. This transaction increased Ozan's direct holdings to approximately 11,627 shares, with an additional 2,220 shares indirectly held by the CFO's spouse. The acquisition is noted to be part of compensation and is exempt under SEC Rules 16b-3(c) and 16b-3(d).
Niagen Bioscience (NASDAQ:NAGE) Stock Rating Upgraded by Freedom Capital
Freedom Capital has upgraded Niagen Bioscience (NASDAQ:NAGE) to a "strong-buy" rating, contributing to a mixed analyst sentiment that still results in an average "Buy" rating and a consensus price target of $10.50. The stock recently traded down to $3.37, below its moving averages, despite beating its latest earnings expectations with revenue of $31.47 million and EPS of $0.07. Institutional ownership by hedge funds and other investors stands at 15.41%.
Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026
Niagen Bioscience CEO Rob Fried will participate in a virtual fireside chat on July 15, 2026, to discuss the company's recently launched pharmaceutical program for rare genetic diseases and aging-related disorders. The chat will also cover Niagen Bioscience's leadership in NAD+ science and provide business updates. This event, hosted by KCSA Strategic Communications, will include a live Q&A session.
Niagen Bioscience (NAGE) CEO adds 1,106 ESPP shares, holds 1.06M directly
Niagen Bioscience's CEO, Robert N. Fried, acquired an additional 1,106 common shares through the company's Employee Stock Purchase Plan at $2.71 per share on June 30, 2026. This transaction is exempt under Rule 16b-3(c) and 16b-3(d). Following this acquisition, Fried directly holds 1,060,087 shares, with additional indirect holdings through various trusts and family members for which he disclaims beneficial ownership.
Form 4 Niagen Bioscience Inc For: 8 July By Investing.com
This article provides details about a Form 4 filing for Niagen Bioscience Inc. on July 8. It indicates that the document is published by Investing.com and was released on July 8, 2026, at 05:22 p.m. The core content highlights the Form 4 filing for NAGE, with a stock performance of -2.32%.
